Visão geral da empresa
A clinical-stage neuropsychiatry company operating under the name Cybin D/B/A Helus Pharma focuses on the development of psychedelic-based therapeutics designed for patients suffering from mental health conditions. The firm's primary asset is CYB003, a deuterated psilocybin analog currently advancing through phase 3 clinical trials aimed at treating major depressive disorder. Helus Pharma operates within the healthcare sector, specifically the biotechnology industry, a segment characterized by high research and development costs and significant regulatory hurdles before products can reach commercialization. The company maintains a market capitalization of $261.45M while employing a workforce of 50 individuals, indicating a lean operational structure typical of early-stage biotech firms. These valuation figures suggest that the market prices the entity based on potential future asset value and clinical trial milestones rather than current cash flow generation, reflecting the inherent risks and long-term horizon associated with bringing novel psychiatric medications to market.
Saúde financeira
The company reports negative net income of $-123,217,320 and an EBITDA of $-119,248,656 over the trailing twelve months, while revenue data is not available in the provided metrics. The substantial gap between the reported net income and the EBITDA figure reveals a significant impact from non-operating expenses or specific accounting adjustments that reduce the bottom line below the operating earnings metric. Helus Pharma generates negative free cash flow of $-69,987,976, which indicates that the company is burning cash to fund its clinical operations and research initiatives rather than generating liquidity from sales. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which signifies that the company has not yet achieved commercial profitability or that revenue is insufficient to cover costs in the current reporting period. The firm holds cash reserves of $206,357 against zero total debt, resulting in a debt-to-equity ratio that is not applicable due to the absence of debt on the balance sheet. This capital structure represents a highly conservative approach regarding leverage, as the company relies entirely on equity financing and internal cash reserves rather than borrowing to fund its operations. Furthermore, the current ratio stands at 13.78, a figure that indicates robust short-term liquidity relative to current liabilities, suggesting the company is well-positioned to meet its immediate obligations despite the lack of traditional debt instruments. Return on Equity is reported at -55.9% and Return on Assets at -31.9%, metrics that reveal the company is currently destroying shareholder value and utilizing its asset base to generate losses rather than returns, a common characteristic for clinical-stage biotechs prior to product approval.
Avaliação de valorização
The trailing twelve-month P/E ratio is not available due to negative earnings, while the forward P/E is listed at -1.65, implying that the market is pricing the stock based on expectations of future earnings recovery or is utilizing alternative valuation models given the current loss position. The price-to-book ratio is 0.95, indicating that the company is trading at approximately 5% below its book value, which suggests the market values the firm at or slightly less than the replacement cost of its net assets. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA of -5.77 are also not available or negative, reflecting the company's inability to generate positive earnings or sales to support traditional multiple-based valuations at this stage of development. The stock has traded between a 52-week low of $4.29 and a 52-week high of $9.83, placing the current trading range within a wide band of volatility typical for speculative biotechnology stocks. The beta value is 1.04, which means the stock's price volatility is slightly higher than the broader market, moving 4% more than the market average during periods of increased investor sentiment shifts. These valuation characteristics highlight the high-risk, high-potential-reward profile often associated with companies in the psychedelic therapeutics space that are still navigating the complex regulatory pathway.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are not available in the provided facts, preventing a direct comparison of growth rates between sales and profitability. Since the company does not pay dividends, the dividend yield and payout ratio are both not applicable, with a payout ratio of 0.0% reflecting the fact that the firm reinvests all available capital, including minimal cash reserves, back into research and development rather than distributing income to shareholders. The absence of a dividend program is consistent with the company's lifecycle stage, where management prioritizes funding clinical trials over providing income to investors. Consequently, the overall growth and income profile is defined entirely by the potential upside from clinical trial success and regulatory approval, rather than current cash yield or historical growth trajectories.